Join or Renew Your Membership Join

Log In

Forgot Password?
Create New Account

Loading... please wait

2005 Annual Meeting | Multiple Sclerosis: Clinical Trials I

Tuesday 04/12/05
03:45 PM - 05:00 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Scientific Platform Session
MS and Related Diseases
No CME available
Event Timeline
03:45 PM - 05:00 PM Abstract 003 - Clinical Results from AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial To Determine the Efficacy and Safety of Natalizumab in Patients with Relapsing Multiple Sclerosis (MS)
03:45 PM - 05:00 PM Abstract 004 - Safety, Tolerability and Immunogenicity of Natalizumab: Results from the AFFIRM Trial
03:45 PM - 05:00 PM Abstract 005 - The Efficacy of Natalizumab on Magnetic Resonance Imaging (MRI) Measures in Patients with Relapsing Multiple Sclerosis (MS): Results from the AFFIRM Trial
Faculty Disclosures
Dennis N. Bourdette, MD, FAAN Dr. Bourdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Magellan Health Care. Dr. Bourdette has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctor's Inc. Dr. Bourdette has stock in Authobahn Therapeutics. Dr. Bourdette has received intellectual property interests from a discovery or technology relating to health care.
Emmanuelle Waubant, MD, PhD, FAAN Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as a Consultant for emerald pharmaceuticals. Dr. Waubant has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for elsevier. The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Biogen. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Ka S. Wong, MD No disclosure on file
Antonio Gil-Nagel, MD Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion.
Elena Lopez Garcia No disclosure on file
No disclosure on file
Patrick K. Kwan, MD, PhD No disclosure on file
Christine Schuhmann No disclosure on file
Gill Webster, PhD No disclosure on file
Bonaventure Ip The institution of Bonaventure Ip has received research support from Hong Kong College of Physicians.
Thomas W. Leung, MD Dr. Leung has nothing to disclose.
Chai Lim No disclosure on file
Sandeep Kumar, MD Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for CRICO.
Neishay Ayub, MD The institution of Dr. Ayub has received research support from Brown Physicians Incorporated. The institution of Dr. Ayub has received research support from Pappitto Opportunity Connection.
Kathie Lin, MD Dr. Lin has nothing to disclose.
Jillian Alderson, MD No disclosure on file